180 Life Sciences Enterprise value
What is the Enterprise value of 180 Life Sciences?
The Enterprise value of 180 Life Sciences Corp. is $8.60M
What is the definition of Enterprise value?
Enterprise value is a measure of a company’s total market value. It is calculated as market capitalization with debt, minority interest, and preferred shares minus total cash and cash equivalents.
ttm (trailing twelve months)
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
Enterprise value of companies in the Health Care sector on NASDAQ compared to 180 Life Sciences
What does 180 Life Sciences do?
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Companies with enterprise value similar to 180 Life Sciences
- Lamtex has Enterprise value of $8.57M
- Enertime SA has Enterprise value of $8.58M
- Invex Therapeutics Ltd has Enterprise value of $8.58M
- Invex Therapeutics Ltd has Enterprise value of $8.58M
- KalNorth Gold Mines has Enterprise value of $8.59M
- SportsHero has Enterprise value of $8.59M
- 180 Life Sciences has Enterprise value of $8.60M
- IDT Australia has Enterprise value of $8.60M
- InsuraGuest Technologies has Enterprise value of $8.60M
- Inventus Mining has Enterprise value of $8.60M
- Virat Crane Industries has Enterprise value of $8.60M
- Black Swan Graphene Inc has Enterprise value of $8.60M
- QMC Quantum Minerals Corp has Enterprise value of $8.61M